Skip to main content

Table 1 Patient characteristics

From: Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer

Variable

Wild-type EGFR

EGFR mutation

p-value

Age

63.1 ± 7.8

60.3 ± 11.8

0.282

Gender (F:M)

8:23

20:10

0.001a

Pathology (ADC:SCC:NOS)

28:1:1

29:1:0

0.611

Smoking status

  

0.007a

Never smoker

11

21

 

Current/former smoker

20

9

 

TNM staging (1:2:3:4)

8:7:5:11

7:4:5:14

0.746

Tumor markers

   

s-CYFRA

7.28 ± 20.28

2.50 ± 1.67

0.201

s-CEA

18.77 ± 46.91

34.61 ± 67.55

0.300

s-SCCA

1.00 ± 1.03

0.84 ± 0.89

0.507

c-CYFRA

85.18 ± 135.79

200.19 ± 208.84

0.014a

c-CEA

21.60 ± 59.05

49.85 ± 110.04

0.214

c-SCCA

9.97 ± 35.36

5.70 ± 19.33

0.562

SUVmax

10.33 ± 5.82

7.01 ± 3.91

0.014a

Log(TLG)

1.80 ± 0.65

1.35 ± 0.70

0.014a

  1. ADC adenocarcinoma, c-CEA cytologic carcinoembryonic antigen, c-CYFRA cytologic CYFRA 21-1, c-SCCA cytologic squamous cell carcinoma antigen, NOS non-small cell carcinoma not otherwise specified, SCC squamous cell carcinoma, s-CEA serum carcinoembyonic antigen, s-CYFRA serum CYFRA 21-1, s-SCCA serum squamous cell carcinoma antigen, SUVmax maximum standard uptake value, log(TLG) natural logarithmic transformation of total lesion glycolysis
  2. astatistically significant values of p < 0.05